This Phase 2 research met its major endpoint.

UCB and Amgen Announce Positive Phase 2 Outcomes of AMG 785/CDP7851 Amgen and UCB announced positive top-line results from their Phase 2 clinical research comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal females with low bone mineral density for the treatment of postmenopausal osteoporosis . This Phase 2 research met its major endpoint, demonstrating significant boosts in lumbar spine bone mineral density at month 12 for the AMG 785/CDP7851 active hands versus the placebo arm. In addition, AMG 785/CDP7851 compared with the two active comparators positively, teriparatide and alendronate over the counter .

XGEVA was accepted and granted Orphan Medication Designation by the FDA, which is reserved for medications that are intended for the treating rare diseases affecting fewer than 200,000 people in the U.S. HCM is usually a significant complication in patients with advanced cancer, including people that have hematologic malignancies, and signifies poor prognosis. The condition results from cancer-driven increases in bone resorption, and if untreated, can lead to renal failing, progressive mental impairment, coma and death. ‘Our continued research of XGEVA reinforces Amgen's ongoing commitment to address the unmet needs of cancer individuals,’ stated Sean E.

Other Posts From Category "traumatology":

Related Posts